Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Abstract Introduction Adverse drug reactions (ADRs) are a major public health concern and
a leading cause of morbidity and mortality in the world. In the case of antiepileptic drugs …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …

Abstract Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL)
belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act …

Abstract The Euro-Esli study was an exploratory pooled analysis of data from 14 European
clinical practice studies, which was conducted to audit the real-world effectiveness, safety …

Introduction: Mesial temporal lobe epilepsy associated with hippocampal sclerosis (MTLE-
HS) is a syndrome that is often refractory to drug treatment. The effects on specific …

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is
blockade of the voltage-gated sodium channel (VGSC). However, in respect to …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

There is currently a lack of guidance on methodology and special considerations for
transitioning patients from oxcarbazepine (OXC) or carbamazepine (CBZ) to …